Lexicon Pharmaceuticals Stock Today
| LXRX Stock | USD 0.80 0.02 2.44% |
Performance0 of 100
| Odds Of DistressOver 84
|
Lexicon Pharmaceuticals is trading at 0.8 as of the 28th of November 2024; that is 2.44 percent decrease since the beginning of the trading day. The stock's open price was 0.82. Lexicon Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Lexicon Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of April 2000 | Category Healthcare | Classification Health Care |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas. Lexicon Pharmaceutcl operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 361.49 M outstanding shares of which 28.65 M shares are now shorted by private and institutional investors with about 7.49 trading days to cover. More on Lexicon Pharmaceuticals
Moving together with Lexicon Stock
| 0.77 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.61 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Lexicon Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Lexicon Stock Highlights
| CEO and President and Director | Lonnel Coats | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsLexicon Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lexicon Pharmaceuticals' financial leverage. It provides some insight into what part of Lexicon Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lexicon Pharmaceuticals (LXRX) is traded on NASDAQ Exchange in USA. It is located in 2445 Technology Forest Boulevard, The Woodlands, TX, United States, 77381 and employs 285 people. Lexicon Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 296.5 M. Lexicon Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 361.49 M outstanding shares of which 28.65 M shares are now shorted by private and institutional investors with about 7.49 trading days to cover.
Lexicon Pharmaceuticals currently holds about 61.97 M in cash with (161.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.34.
Check Lexicon Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationLexicon Pharmaceuticals maintains a total of 361.49 Million outstanding shares. The majority of Lexicon Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Lexicon Pharmaceuticals to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Lexicon Pharmaceuticals. Please pay attention to any change in the institutional holdings of Lexicon Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Lexicon Ownership Details
Lexicon Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Pinnacle Associates Inc | 2024-09-30 | 1.7 M | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 1.4 M | |
| Point72 Asset Management, L.p. | 2024-09-30 | 1.2 M | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 1.2 M | |
| Northern Trust Corp | 2024-09-30 | 1.1 M | |
| Braidwell Lp | 2024-09-30 | 801.6 K | |
| Wellington Management Company Llp | 2024-06-30 | 738.6 K | |
| Hennion & Walsh Asset Management Inc | 2024-09-30 | 731.1 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 708.1 K | |
| Artal Group S A | 2024-06-30 | 175.1 M | |
| Fmr Inc | 2024-09-30 | 49.9 M |
Lexicon Pharmaceuticals Historical Income Statement
Lexicon Stock Against Markets
Lexicon Pharmaceuticals Corporate Management
| Kenneth MD | Senior Assurance | Profile | |
| Chas Schultz | Executive Advocacy | Profile | |
| Robert MD | Consultant Director | Profile | |
| Tom Garner | Senior Officer | Profile | |
| Desiree Gendron | Vice Training | Profile |
Additional Tools for Lexicon Stock Analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.